The global attention deficit hyperactivity disorder therapeutics market size to reach USD 17.5 billion by 2024 from USD 27.1 billion in 2019. The market is growing at a CAGR of 9.09% during the forecast period.
Attention deficit hyperactivity is a neurodevelopmental disorder which damages and envelops symptoms of impulsivity and hyperactivity. Treating and controlling the disease with the help of technology defines, neurobehavioral because the way the brain affects learning, behaviour and emotion.
MARKET DRIVERS
The growing incidence of Attention deficit hyperactivity disorder across the world is fundamentally driving the market growth.
The causes of ADHD are still indistinct, although genetic presence is observed in many cases. As per the data given by the centres for Disease Control and Prevention (CDC) in 2016, around 6.1 million individuals, including 388,000 children aged 2–5 years, 4 million 6–11 years, and 3 million 12–17 years, were diagnosed with ADHD in the U.S. besides, boys are more likely to be diagnosed than girls.
Frequency of ADHD is rising at a higher rate, which is to drive the growth of global attention-deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder. The ADHD therapeutics market is mostly driven by the rough impact of unstable lifestyles and additives in children's diet, increasing incidence of ADHD within the 4 to 17 year age group. Moreover, increasing awareness concerning syndrome among physicians and patients, and opinion-based as a result of the lack of regular diagnostic tests is anticipated to fuel revenue growth of the worldwide ADHD market in the coming future.
Additionally, increasing advancements in the medical field, a growing number of researches in neurosciences, raising awareness about mental illness among people are fuelling the market growth to a considerable extent. Furthermore, expanding the focus of biotechnology & pharmaceutical companies into developing the innovative therapeutics for ADHD are driving the growth of the global attention deficit hyperactivity disorder therapeutics market.
MARKET CHALLENGES
The high cost of the ADHD medications, improper reimbursement policies, and side effects related to ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes) are restraining the growth of global attention deficit hyperactivity disorder therapeutics market.
All the side effects associated with ADHD drugs are affecting the lives of the patients, which will be the reason for hampering revenue growth of the attention-deficit hyperactivity disorder therapeutics market in the given forecast period. Problems like allergic reactions to medicine, medical conditions like coronary artery disease, kidney disease, seizures are associated with Attention deficit hyperactivity disorder medicines.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By Type, Production Technologies and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on the global attention deficit hyperactivity disorder therapeutics market has been segmented and sub-segmented based on the Type, Production Technologies and Region.
ADHD Therapeutics Market - Treatment by Medication:
Based on the medication types, stimulants are expected to emerge as the drugs of choice, both among physicians and patients worldwide. Amphetamine is also to gain popularity over the forecast period.
ADHD Therapeutics Market - Treatment by Psychotherapy:
ADHD Therapeutics Market - Treatment by Education or Training:
Regional Analysis
North America commanded the highest share of 36.0% of the global attention deficit hyperactivity disorder therapeutics market in 2019. In contrast, Asia-Pacific is estimated to grow at the highest CAGR of 12.30% during the forecast period 2019 to 2024.
North America leads the ADHD therapeutics market with the largest market share. The growing rate of patients in Attention deficit hyperactivity disorder and high expenditure on healthcare is responsible for the regional market growth. It is the reason behind the large revenue pocket of the local market in the U.S. The region would hold its leading position in the global Attention deficit hyperactivity disorder therapeutics market in the forecast period.
European Attention deficit hyperactivity disorder market holds the second-most position along with the emerging technology and digital medicines. The affluent medical device market and growing healthcare expenditure are responsible for the growth of the market.
The Asia Pacific region is also increasing in the Attention deficit hyperactivity disorder therapeutics market. The factors which are responsible for the growth of the market are the unmet needs and sizeable patient population also the availability of lower-cost drugs for the ADHD treatment. Moreover, improving the economy in the region is acting as a key to the success of pushing up the regional market and boosting the healthcare sector. Private organizations and the increased funding from the population are responsible for the growth of the regional market. The explosion of healthcare insurance in many countries like Malaysia, Thailand, and Vietnam are expected to drive the ADHD market in the Asia Pacific region. Also, the availability of the new treatments along with the technology, affect the growing demand and to propel the growth of the regional ADHD therapeutics market.
List of key market players dominating the global attention deficit hyperactivity disorder therapeutics market profiled in the report are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Treatment By Medication
5.2.1 Introduction
5.2.2 Stimulants
5.2.2.1 Introduction
5.2.2.2 Amphetamines
5.2.2.3 Methylphenidate
5.2.2.4 Dextroamphetamine
5.2.2.5 Dexmethylphenidate
5.2.3 Non-Stimulants
5.2.3.1 Introduction
5.2.3.2 Atomoxetine
5.2.3.3 Bupropion
5.2.3.4 Guanfacine
5.3 Treatment By Psychotherapy
5.3.1 Introduction
5.3.2 Behavior Therapy
5.3.3 Cognitive Behavioral Therapy
5.3.4 Interpersonal Psychotherapy
5.3.5 Family Therapy
5.4 Treatment By Education or Training
5.3.1 Introduction
5.3.2 Parent Management Training
5.3.3 Social Skills Training
5.3.4 School-Based Interventions
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle East
6.5.3 South Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Shire plc (Ireland)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Neos Therapeutics, Inc. (U.S.)
8.3 Eli Lilly and Company (U.S.)
8.4 Pfizer Inc. (U.S.)
8.5 Alcobra Ltd. (Israel)
8.6 Supernus Pharmaceuticals, Inc. (U.S.)
8.7 Noven Pharmaceuticals, Inc. (U.S.)
8.8 Novartis AG (Switzerland)
8.9 Johnson & Johnson (U.S.)
8.10 Curemark, LLC., (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
